Peptide
Degarelix (Firmagon)
Degarelix is a third-generation GnRH antagonist peptide. FDA-approved for advanced prostate cancer. Phase III trial (CS21) showed 97.2% achieved testosterone ≤0.5 ng/mL. Achieves castration in 96% of patients by day 3 (vs 0% with leuprolide). No testosterone flare or need for antiandrogen flare protection. Median PSA significantly lower at days 14 and 28 vs leuprolide (p<0.001).
- Updated
- How we grade
- 57 studies cited
Research notice. This page is for education and research. Peptides may not be FDA-approved for human use and may only be legally available for research. Talk to a qualified clinician before considering any peptide.
- Best evidence
- Grade A
- Conditions studied
- 1
- Outcomes
- 11
- Graded outcomes
- 5303
Evidence by condition
- Strong
- Moderate
- Limited
- Very limited
General
Key findings
- Disease ControlImproves (the measure goes up)
- Testosterone SuppressionImproves (the measure goes down)
- PSA SuppressionImproves (the measure goes down)
Studies cited
57 studies from PubMed
- Testosterone recovery after androgen deprivation therapy.
- Exploration of cardiac adverse events associated with relugolix and degarelix: a multi-center pharmacovigilance study based on the FAERS database.
- Comparative Cardiovascular Safety of Gonadotropin-releasing Hormone Antagonists and Agonists Among Patients Diagnosed with Prostate Cancer: A Systematic Review and Meta-analysis of Real-world Evidence Studies.
- Risk of cardiovascular disease following degarelix versus gonadotropin-releasing hormone agonists in patients with prostate cancer: a systematic review and meta-analysis.
- Comparing the risk of cardiovascular disease between degarelix and gonadotropin-releasing hormone agonists:a systematic review and meta-analysis.
- Effectiveness and safety of degarelix compared to GnRH agonists for prostate cancer: a systematic review and meta-analysis.
- A systematic review and meta-analysis of cardiovascular disease risk with degarelix and GnRH agonists in prostate cancer
- Testosterone bounce predicts favorable prognoses for prostate cancer patients treated with degarelix.
- Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.
- Risk of cardiovascular events following intermittent and continuous androgen deprivation therapy in patients with nonmetastatic prostate cancer.
- Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer.
- The landscape of androgen deprivation therapies for the treatment of advanced prostate cancer.
- Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
- Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer.
- Effects of Catheter-Based Renal Denervation in Hypertension: A Systematic Review and Meta-Analysis.
- Reversal of Lactate and PD-1-mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate Cancer.
- Short-Term DAPT and DAPT De-Escalation Strategies for Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis.
- Advances with androgen deprivation therapy for prostate cancer.
- The Efficacy and Safety of Relugolix Compared with Degarelix in Advanced Prostate Cancer Patients: A Network Meta-analysis of Randomized Trials.
- A review of clinical evidence to assess differences in efficacy and safety of luteinizing hormone-releasing hormone (LHRH) agonist (goserelin) and LHRH antagonist (degarelix).
- Real-World Evidence Prediction of a Phase IV Oncology Trial: Comparative Degarelix vs Leuprolide Safety.
- Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial
- Degarelix as a neoadjuvant hormonal therapy for acute urinary tract toxicity associated with external beam radiotherapy for intermediate- and high-risk prostate cancer: a propensity score matched analysis.
- Does Exist a Differential Impact of Degarelix Versus LHRH Agonists on Cardiovascular Safety? Evidences From Randomized and Real-World Studies.
- Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.
- Efficacy and safety of degarelix in patients with prostate cancer: Results from a phase III study in China.
- Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design.
- GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression.
- Effect of Degarelix, a Gonadotropin-Releasing Hormone Receptor Antagonist for the Treatment of Prostate Cancer, on Cardiac Repolarisation in a Randomised, Placebo and Active Comparator Controlled Thorough QT/QTc Trial in Healthy Men.
- Degarelix treatment is compatible with diabetes and antithrombotic therapy in patients with prostate cancer.
- Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
- Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trials.
- Degarelix for the treatment of advanced prostate cancer compared with GnRh-Agonists: a systematic review and meta-analysis.
- A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer.
- Degarelix versus goserelin plus bicalutamide therapy for lower urinary tract symptom relief, prostate volume reduction and quality of life improvement in men with prostate cancer: a systematic review and meta-analysis.
- Degarelix: a review of its use in patients with prostate cancer.
- Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233).
- The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients
- Experience with degarelix in the treatment of prostate cancer
- Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer.
- Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses.
- Evaluation of degarelix in the management of prostate cancer
- A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer
- Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study
- Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer
- Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer
- Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics
- Degarelix and its therapeutic potential in the treatment of prostate cancer
- Degarelix: a novel gonadotropin-releasing hormone blocker for the treatment of prostate cancer.
- Degarelix for prostate cancer.
- Degarelix: a new approach for the treatment of prostate cancer.
- Degarelix (firmagon) for prostate cancer.
- Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer.
- Degarelix acetate for the treatment of prostate cancer.
- The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer
- Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker--results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer.
- Drug evaluation: Degarelix--a potential new therapy for prostate cancer.